Evidence map›Paper›PMID 42853423›Full record

ArticleAnnals of hematology2026

Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma.

Karin Potthoff, Jens Uhlig, Eyck von der Heyde, Christoph Losem, Arnd Nusch, Andreas Ammon, Björn Schöttker, Holger Schulz, Jan Janssen, Manfred Welslau and 8 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02970747 (A Non-interventional Study of Carfilzomib), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02970747 completednot on this map

A Non-interventional Study of Carfilzomib (Kyprolis®) in Combination With Lenalidomide (Revlimid®) and Dexamethasone or Carfilzomib in Combination With Dexamethasone Alone or Carfilzomib in Combination With Daratumumab (Darzalex®) and Dexamethasone in Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy

TypeobservationalSponsoriOMEDICO AGRan2016 to 2025Enrolled359ConditionsMultiple Myeloma in RelapseArmsCarfilzomib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Karin PotthoffMedical Department, iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany. manuscript@iomedico.com.
Jens UhligPraxis Dr. Jens Uhlig, Naunhof, Germany.
Eyck von der HeydeOnkologische Schwerpunktpraxis, Hannover, Germany.
Christoph LosemRheinlandklinikum, Grevenbroich, Germany.
Arnd NuschPraxis für Hämatologie und internistische Onkologie, Ratingen, Germany.
Andreas AmmonOSP Göttingen, Göttingen, Germany.
Björn SchöttkerHämatologisch-Onkologische Schwerpunktpraxis, Würzburg, Germany.
Holger SchulzPraxis Internistischer Onkologie und Hämatologie (PIOH), Frechen, Germany.
Jan JanssenGemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany.
Manfred WelslauMVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany.
Stefan WilopMVZ West GmbH Würselen Hämatologie-Onkologie, Würselen, Germany.
Corinne VannierMedical Department, iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany.
Johanna HanselmannBiostatistics, iOMEDICO, Freiburg im Breisgau, Germany.
Laura SerrerClinical Operations, iOMEDICO, Freiburg im Breisgau, Germany.
Sandra M WoernerMedical Department, iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany.
Sophie KoszinowskiMedical Department, iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany.
Monika EngelhardtDepartment of Hematology and Oncology, Interdisciplinary Cancer Center, Faculty of Freiburg, University of Freiburg, Freiburg, Germany.
Wolfgang KnaufCentrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prospective, multicenter, non-interventional study CARO (NCT02970747) investigated adherence, effectiveness, quality of life and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) in German routine clinical practice. CARO included 359 patients at 69 sites and evaluated three carfilzomib-based treatment regimens: Carfilzomib with lenalidomide and dexamethasone (KRd), with dexamethasone only (Kd) or with daratumumab and dexamethasone (KdD). Across cohorts, patients' adherence to carfilzomib was > 90%, while effectiveness was in line with previous data from both randomized clinical trials and real-world studies. Median PFS (95% CI) was 17.5 months (14.5, 24.7 [KRd]), 13.4 months (7.3, 18.1 [Kd]) and 20.1 months (10.9, 26.6 [KdD]), respectively. Median OS was 38.9 months (31.5, 51.4 [KRd]), 24.6 months (17.8, 36.8 [Kd]) and not reached (21.9, NA [KdD]). Patients' quality of life remained stable during treatment, while pain parameters improved after 6 months of treatment. CARO provides real-world evidence that KRd, Kd, and KdD combinations achieve clinically meaningful outcomes in everyday practice and demonstrates patients' excellent treatment adherence.ClinicalTrials.gov identifier: NCT02970747.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaOligopeptidesPatient Reported Outcome MeasuresQuality of LifeAdultAgedAged, 80 and overAntibodies, MonoclonalDexamethasoneFemaleGermanyHumansLenalidomideMaleMiddle AgedAntibodies, MonoclonalcarfilzomibdaratumumabDexamethasoneLenalidomideOligopeptidesAntibody-based immunotherapyCarfilzomibChemotherapeutic approachesMyeloma

Identifiers

PMID42853423

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.